MEMORIAL HOSPITAL AND CANCER AND ACUTE LEUKEMIA GROUP B

描述（改编自申请人的摘要）：这是第一个 癌症及白血病B组研究资助申请书 纪念斯隆-凯特琳癌症中心（MSKCC）作为主要的活动 成员机构。 MSKCC的使命是致力于临床和实验室 与癌症治疗和生物学相关的研究。 以前是一个附属机构 1996年2月，MSKCC成为纽约医院的主要成员。 这 从附属会员转变为主要会员代表了我们的承诺， 参加一个基础广泛的合作小组， 国家组和组间随机试验， 国家议程纳入我们广泛的临床试验计划。 强大的研究 CALGB和MSKCC之间已经存在相互作用。 拉里·诺顿医学博士 乳房委员会主席和Jimmie Holland，医学博士第一个也是唯一一个主席， 心理肿瘤学委员会，两者在形成小组和 国家临床试验。 此外，南希·凯梅尼，医学博士，是下列国际组织的成员 GI委员会和CALGB 9481医学肿瘤学主席，研究 结直肠癌肝内化疗 转移 我们计划增加在这些领域的参与，克利福德 Hudis，医学博士，安德鲁·塞德曼医学博士已经在积极地向 乳房委员会 Alice Kornblith博士，领导了几个心理肿瘤学 努力，和罗素Porenoy，医学博士，雷蒙德·韦森博士将加入 姑息治疗和少数民族问题的努力。 委员会的参与 扩大，与19 MSKCC教师被任命为12个委员会。 议定书 应计款项增加，1996年3月1日至1997年5月1日期间有69笔， 自1996年12月以来， 增加临床试验累积将导致 来自新激活的CALGB治疗性和非治疗性研究， 增加疾病和模式委员会，并通过引进新药物和 MSKCC正在开发的生物制剂纳入集团研究。 这种集成 正在进行中。 R.S. K Chaganti博士，将参加白血病/淋巴瘤 相关科学研究提供了比较的介绍 基因组杂交用于恶性淋巴瘤的研究。 应计自 与麦吉尔大学的联系将增加MSKCC在CALGB的活动。 MSKCC期待着参与CALGB的优秀群体科学。

DESCRIPTION (adapted from the applicant's abstract): This is the first application for support of Cancer and Leukemia Group B (CALGB) research activities by Memorial Sloan-Kettering Cancer Center (MSKCC) as a Main Member institution. MSKCC's mission is devoted to clinical and laboratory research related to cancer treatment and biology. Previously an affiliate of the New York Hospital, MSKCC became a Main Member in February 1996. This change from affiliate to Main Member represents our commitment to participate in a broad-based cooperative group in order to participate in national group and intergroup randomized trials and to interdigitate the national agenda into our extensive clinical trials program. Strong research interactions already exist between CALGB and MSKCC. Larry Norton, M.D., Chair, Breast Committee, and Jimmie Holland, M.D. first and only Chair, Psycho-Oncology Committee, both play dominant roles in shaping group and national clinical trials. In addition, Nancy Kemeny, M.D., is a member of the GI Committee and Medical Oncology Chair of CALGB 9481, studying intrahepatic chemotherapy in colorectal cancer patients with hepatic metastases. We plan to augment participation in these areas, and Clifford Hudis, M.D., and Andrew Seidman, M.D., are already actively presenting to the Breast Committee. Alice Kornblith, Ph.D., leads several psycho-oncology efforts, and Russell Porenoy, M.D., and Raymond Wesson, Ph.D., will join palliative care and minority issue efforts. Committee participation has expanded, with 19 MSKCC faculty appointed to 12 committees. Protocol accrual has increased, with 69 credits between 3/1/96 and 5/1/97, and 47 credits since 12/96 alone. Increased clinical trial accrual will result from newly activated CALGB therapeutic and nontherapeutic studies from additional disease and modality committees and, by introducing new drugs and biologics under development at MSKCC, into Group studies. This integration is under way. R.S.K. Chaganti, Ph.D., will participate in Leukemia/Lymphoma Correlative Sciences studies by providing the introduction of comparative genomic hybridization into the study of malignant lymphomas. Accrual from affiliation with McGill University will augment MSKCC activities in CALGB. MSKCC looks forward to participation in CALGB's excellent group science.